Key Highlights
- Nuvation Bio (NYSE:NUVB) reported third-quarter total Revenue of USD 45.0 million, versus USD 13.1 million a year earlier, including USD 27.5 million of net IBTROZI product revenue.
- The net loss narrowed to USD 41.9 million, or USD 0.12 per share, from USD 55.8 million, or USD 0.16, while the nine-month loss was USD 99.3 million against USD 168.0 million.
- Collaboration and license agreements revenue rose to USD 17.5 million from USD 5.4 million, helped by a USD 5.0 million sales-based milestone from Innovent and USD 7.6 million more product Supply revenue.
- Cash, cash equivalents and marketable securities were USD 663.4 million at September 30, 2026, which the company says should fund operating and Capital needs for at least the next 12 months.
IBTROZI Launch Drives Revenue Past USD 45 Million
Nuvation Bio (NYSE:NUVB), a global oncology company founded in 2018, filed its Quarterly Report on November 4, 2026. Net product revenue from U.S. sales of IBTROZI, its treatment for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer, was USD 27.5 million, compared with USD 7.7 million in the third quarter of 2025. Nine-month IBTROZI revenue was USD 69.2 million against USD 9.0 million. The drug launched in the United States in June 2025 after FDA approval on June 11, 2025, so the prior-year base is small. Nine-month total revenue was USD 159.9 million versus USD 21.0 million, boosted by a license payment from a new partner.
Collaboration Income, Eisai Deal and Label Update
In January 2026 Nuvation Bio announced a Partnership with Eisai to commercialize taletrectinib, the active ingredient in IBTROZI, in Europe and other territories outside the United States, China and Japan. The upfront payment lifted nine-month license revenue by USD 58.7 million. The European Medicines Agency validated the Marketing authorisation application in March 2026. In September 2026 the FDA approved a label update reflecting a median duration of response of 49.7 months in treatment-naive patients in the TRUST-I study. In August 2026 the FDA granted Fast Track Designation to safusidenib, an investigational brain-penetrant inhibitor of mutant IDH1 being tested in glioma and astrocytoma. Royalty revenue rose USD 2.4 million in the quarter, while Research and Development service revenue fell USD 2.9 million.
Losses Persist Despite Cash of USD 663.4 Million
Cost of sales rose to USD 2.1 million from USD 0.3 million as IBTROZI sales grew. The company has recorded net losses every year since inception and carries an accumulated Deficit of USD 1,214.7 million. It expects larger expenses as it advances trials, pursues approvals and builds out commercial activity, and says it will need substantial additional funding over time through equity, debt, grants or collaborations if product revenue does not suffice. Raising funds through partnerships could require giving up rights to products or technology. The filing gives no numerical guidance, consensus or price move. Its confirmatory and adjuvant trials, including TRUST-III and TRUST-IV for taletrectinib, remain ongoing.
Where Things Stand
The loss is narrowing, but the pace depends on IBTROZI sales and partner payments. Nuvation Bio (NYSE:NUVB) cut its quarterly loss to USD 41.9 million as product revenue more than tripled, and a USD 663.4 million cash and securities balance gives roughly a year of coverage by the company's own statement. Offsetting that, one-time license income inflates the nine-month comparison, and costs are expected to rise. Watch IBTROZI sales growth, the European review, safusidenib trials and the next financing signals.




_11_19_2026_18_08_46_525309.jpg)

Please wait processing your request...